eNeurologicalSci最新文献

{"title":"The impact of COVID-19 pandemic on patients with Huntington's disease and care-givers: A French survey","authors":"Sara Meoni ,&nbsp;Elena Moro","doi":"10.1016/j.ensci.2024.100517","DOIUrl":"10.1016/j.ensci.2024.100517","url":null,"abstract":"<div><p>Although the impact of the first wave of the COVID-19 pandemic on people with several neurological diseases has been largely investigated, little is available concerning people with Huntington's disease (HD).</p><p>The main objective of the study was to interview people with HD and their caregivers in the Auvergne-Rhone Alpes region, France.</p><p>The interview consisted of 16 items concerning general and medical information, and the impact of the first wave of COVID-19 pandemic on the medical care of people with HD and on their caregivers. The questionnaire was made available as online survey from October 1st, 2020 until November 15th, 2020.</p><p>Fifty-two subjects participated (13 men, 39 women, mean age of 47.3 ± 15.5 years). Almost half participants (48%) experienced a worsening of pre-existing symptoms, with new-onset symptoms in the 44% of cases. The most frequent worsening was reported in gait and balance issues (67%), fatigue (58%), anxiety (50%), and depression (50%). The 70.8% of participants reported an inappropriate overall care of HD due to long delays to access medical care (30%) and other health care teams (60%). More than half of the participants (54.2%) reported that the COVID-19 pandemic had a negative impact on their caregiver/family.</p><p>Our findings emphasize the negative impact of the first wave of COVID-19 pandemic on the healthcare of HD population and their caregivers. Not only some symptoms were aggravated, but new symptoms appeared during the pandemic. In the future, health policies should be considered to improve the care of patients with rare diseases such as HD.</p></div>","PeriodicalId":37974,"journal":{"name":"eNeurologicalSci","volume":"36 ","pages":"Article 100517"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2405650224000248/pdfft?md5=a3543e8bd9c10af63a9f11a7f6618ae5&pid=1-s2.0-S2405650224000248-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141838811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Candida dubliniensis meningitis in an immunocompetent patient: A case report and review of the literature","authors":"Denis Babici ,&nbsp;Ali A. Mohamed ,&nbsp;Olivia Mattner ,&nbsp;Jessica Canosa ,&nbsp;Willy Gan ,&nbsp;Pooja Patel","doi":"10.1016/j.ensci.2024.100519","DOIUrl":"10.1016/j.ensci.2024.100519","url":null,"abstract":"<div><h3>Objective</h3><p>We present the fifth case of candida dubliniensis meningitis in a young immunocompetent host and suggest extracorporeal membrane oxygenation (ECMO) as a potential risk factor for colonization.</p></div><div><h3>Methods</h3><p>A 22-year-old immunocompetent female presented with a diagnosis of bacterial meningitis. Two years prior, she received ECMO for Covid-19 pneumonia complicated by viral myocarditis &amp; Takutsobo cardiomyopathy. Following discharge, she reported headaches of increasing intensity, all refractory to treatments. Brain magnetic resonance imaging (MRI) was inconclusive. Two weeks prior to her presentation, she was admitted for worsening headaches with cranial nerve VI palsy. Lumbar puncture (LP) revealed white blood cell count (WBC) of 166 cells/μL with neutrophilic predominance and her symptoms progressed, despite 5 days of treatment with broad spectrum antibiotics. All cultures returned negative.</p></div><div><h3>Results</h3><p>At her current presentation, repeat LP revealed 835 WBC/mm3, 225 mg/dL protein, and 4 mg/100 mL glucose. Brain MRI revealed nodular enhancement in the brainstem and communicating hydrocephalus. MRI of the lumbar spine revealed meningeal enhancement. Cerebrospinal fluid (CSF) cultures came back positive for C.dubliniensis. Treatment began with Amphotericin B and Flucytosine.</p></div><div><h3>Discussion</h3><p>When clinical suspicion for fungal meningitis is high, repeate LP and CSF analysis is indicated to establish a definitive diagnosis and begin treatment. Additional studies are needed to confirm risk factors, like ECMO, for the colonization of C.dubliniensis, which likely predisposes individuals to invasive candidiasis.</p></div>","PeriodicalId":37974,"journal":{"name":"eNeurologicalSci","volume":"36 ","pages":"Article 100519"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2405650224000261/pdfft?md5=9a8d0f3e4b9a66b314f788e24658e0ae&pid=1-s2.0-S2405650224000261-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141845723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute Motor Conduction Block Neuropathy After Initiation of Omalizumab: Case Report and Literature Review for Possible Causality","authors":"Hosna S. Elshony ,&nbsp;Abdulaziz Al-Ghamdi","doi":"10.1016/j.ensci.2024.100512","DOIUrl":"10.1016/j.ensci.2024.100512","url":null,"abstract":"<div><h3>Background</h3><p>Omalizumab is an established therapy for allergic conditions, yet its neurological effects remain underexplored compared to other biological agents.</p></div><div><h3>Case description</h3><p>A 45-year-old male with asthma developed acute quadriparesis one week after receiving the first dose of omalizumab. Electrophysiological studies have shown partial motor conduction block in multiple nerves, with reduced CMAP amplitudes and absent F-waves in others. CSF showed cyto-albuminous dissociation. The diagnosis was a variant of Guillain-Barré syndrome. Despite intravenous immunoglobulin (IVIG) therapy, the patient experienced persistent neuropathic symptoms.</p></div><div><h3>Discussion</h3><p>The patient presented with acute quadriparesis devoid of sensory or cranial nerve involvement, suggestive of a variant of Guillain-Barré syndrome (GBS) known as acute motor conduction block neuropathy (AMCBN). Electrophysiological studies have indicated conduction block without demyelination, implicating axonal degeneration. Despite negative findings for common etiologies, the temporal association between omalizumab administration and symptom onset suggests a potential link, supported by criteria for drug-induced illness. Conflicting evidence exists regarding omalizumab's neurological effects, with proposed mechanisms including autoimmune reactions and mast cell dysfunction. Comparisons to TNF-α antagonists highlight similar neuropathy patterns, indicating a need for further research to clarify omalizumab's neurotoxicity.</p></div><div><h3>Conclusion</h3><p>In conclusion, while omalizumab holds promise for allergic conditions, including chronic urticaria, its potential impact on peripheral nerves necessitates vigilance among clinicians. Further studies are imperative to ascertain the risk-benefit profile and elucidate underlying mechanisms and risk factors of neurological complications associated with omalizumab therapy.</p></div>","PeriodicalId":37974,"journal":{"name":"eNeurologicalSci","volume":"36 ","pages":"Article 100512"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2405650224000194/pdfft?md5=b804096e2d01e17529386f9194ed4405&pid=1-s2.0-S2405650224000194-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141395216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spontaneous subarachnoid hemorrhage in a referral health Centre in Central Africa","authors":"Daniel Gams Massi ,&nbsp;Mikael Doufiene Pazeu ,&nbsp;Mathieu Motah ,&nbsp;Annick Melanie Magnerou ,&nbsp;Caroline Kenmegne ,&nbsp;Salomon Mbahé ,&nbsp;Njankouo Yacouba Mapoure","doi":"10.1016/j.ensci.2024.100518","DOIUrl":"10.1016/j.ensci.2024.100518","url":null,"abstract":"<div><h3>Background</h3><p>Spontaneous subarachnoid hemorrhage (sSAH) is a medicosurgical emergency with high morbidity and mortality. The aimed of this study was to describe the clinical features and outcome of sSAH in Cameroon.</p></div><div><h3>Methods</h3><p>We reviewed medical records of patients aged ≥15 years old, admitted for sSAH from Januray 2011 to December 2020 in the Douala General Hospital. The diagnosis of sSAH was confirmed by neuroimaging (CT scan or MRI). Clinical and radiological severities were assessed by the WFNS score and the modified Fisher score respectively. Factors associated to in-hospital mortality was identified using cross-table (RR and 95%CI).</p></div><div><h3>Results</h3><p>Among the 111 cases of sSAH reviewed in emergencies records, we included 70 patients. The mean age was of 55.6 ± 13.6 years. Female were predominant (57.1%). Altered consciousness was the main clinical feature (55.7%). The WFNS score was grade 4–5 in 54.3% of patients. And 75.7% of cases presented a modified Fisher score of 3–4. Ruptured of intracranial aneurysm was the most common etiology (46.2%). Endovascular treatment and/or surgical treatment were not avaible. Hospital-based mortality was 40% and factor associated with death were Altered consciousness (RR: 4.3, 95%CI:1.52–12.33, <em>p</em> = 0.004), coma (RR: 23.9, 95%CI:2.85–200.62, p = 0.004), WFNS grade 5 (RR: 18.2, 95%CI:3.7–92.3, <em>p</em> &lt; 0.001), and hospital length ≤ 7 days (RR: 13.5, 95%CI:4.28–42.56, p &lt; 0.001).</p></div><div><h3>Conclusion</h3><p>Mortality and disability of sSAH are still high in our setting. Further studies with prospective follow up of patients are needed to determine the long-term outcome of these patients.</p></div>","PeriodicalId":37974,"journal":{"name":"eNeurologicalSci","volume":"36 ","pages":"Article 100518"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S240565022400025X/pdfft?md5=f429d6f74a472657398a70b5acf9a9b1&pid=1-s2.0-S240565022400025X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141949916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sertraline treatment for paroxysmal nonkinesigenic dyskinesia comorbid with anxiety and depression","authors":"Munetsugu Hara ,&nbsp;Toyojiro Matsuishi ,&nbsp;Satoru Takahashi ,&nbsp;Yushiro Yamashita","doi":"10.1016/j.ensci.2024.100520","DOIUrl":"10.1016/j.ensci.2024.100520","url":null,"abstract":"<div><p>Familial paroxysmal non-kinesigenic dyskinesia, which is a major form of paroxysmal dyskinesias, is characterized by intermittent attacks that include one side, subsequently spreading to the other side, involving the limbs and face, and is triggered by caffeine, alcohol, emotional stress, fatigue, and sleep deprivation, but not by sudden movement. A 26-year-old man had experienced dystonic movements and a choreiform right arm spreading to his arms, legs, and face since the age of one year. Oral dyskinesias and, rarely, dysarthria were also observed. Attacks lasting approximately five minutes occurred several times per day. Over three generations, his family members inherited a c.26C &gt; T (p. Ala9Val) missense mutation in exon 1 of <em>PNKD/MR-1</em> in an autosomal dominant manner and reported similar symptoms with clinical manifestations ranging from mild to severe. His scores on the Self-Rating Depression Scale, State–Trait Anxiety Inventory, and Profile of Mood States were high. This suggests that the patient also had comorbidities of anxiety and depression. The patient's attacks decreased from two times per week to once every two months, and his State–Trait Anxiety Inventory score decreased by 5–10 points on treatment with clonazepam and sertraline, allowing his condition to become stable enough that he was able to participate in society. Drug therapy with clonazepam and sertraline is the preferred treatment for reducing attacks in PNKD patients with strong anxiety and depression.</p></div>","PeriodicalId":37974,"journal":{"name":"eNeurologicalSci","volume":"36 ","pages":"Article 100520"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2405650224000273/pdfft?md5=a68d5aa26f3d11f9ed0a4fab36d4ee5b&pid=1-s2.0-S2405650224000273-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141951461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful use of intra venous tenecteplase for acute ischemic stroke in pregnancy","authors":"Balamurugan Namasivayam ,&nbsp;Chitra Sengodan ,&nbsp;Lavanya Mohanasundaram ,&nbsp;Sathya Chinna Gounder ,&nbsp;Madunisha Sivakumar","doi":"10.1016/j.ensci.2024.100510","DOIUrl":"https://doi.org/10.1016/j.ensci.2024.100510","url":null,"abstract":"<div><p>Intravenous thrombolysis (IVT) with tenecteplase or alteplase is the standard of care in, patients with Acute Ischemic Stroke (AIS) presenting within 3–4.5 h. However here, are no established guidelines for such treatment during pregnancy. We report a case, of AIS in third trimester of pregnancy successfully treated with Tenecteplase. To the, best of our knowledge, this is the first and only case of acute ischemic stroke in, pregnancy treated with Tenecteplase.</p></div>","PeriodicalId":37974,"journal":{"name":"eNeurologicalSci","volume":"36 ","pages":"Article 100510"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2405650224000170/pdfft?md5=1aa509a542fd1f1171eb3ac3e99182ec&pid=1-s2.0-S2405650224000170-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141429011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spinal melanoma with optic neuropathy –rare manifestation of Neurocutaneous melanosis and PET-MRI findings","authors":"Dipti Baskar ,&nbsp;Seena Vengalil ,&nbsp;Priyanka Chakkera ,&nbsp;Sai Bhargava Sanka ,&nbsp;Pritam Raja ,&nbsp;Karthik Kulanthaivelu ,&nbsp;Preetham Patavardhan ,&nbsp;Keerti Sitani ,&nbsp;Yasha T. Chickabasaviah ,&nbsp;Nupur Pruthi ,&nbsp;Atchayaram Nalini","doi":"10.1016/j.ensci.2024.100504","DOIUrl":"10.1016/j.ensci.2024.100504","url":null,"abstract":"<div><p>Neurocutaneous melanocytosis (NCM) is a rare, sporadic neuroectodermal dysplasia characterized by the presence of large or multiple congenital cutaneous nevi and melanocytic deposits in the central nervous system. Hitherto, unreported we describe a case of NCM with optic neuropathy and spinal cord melanoma from India. A 20 year-old-lady had headache and vomiting for 3 months followed by consecutive profound painless visual impairment. Visual acuity was counting of fingers at 1 m distance in both eyes with normal fundus. There were no symptoms of spinal cord involvement. Clinical examination showed multiple small to large melanocytic nevi over the face and body. Muscle power was normal. Tendon reflexes were exaggerated. Visual evoked potential showed bilateral prolonged P100 latency (Right eye - 144 msec; Left eye - 151 msec). Brain MRI revealed leptomeningeal enhancement of brainstem, cerebellum, oculomotor and facial-abducent nerve complex without optic nerve involvement. MRI spine showed extensive dorsal thoracic cord epidural lesion extending along the entire thoracic cord segment with dorsal cord compression. Positron Emission Tomography (PET) imaging showed Fludeoxyglucose F18 (FDG) avidity along D1-D12 levels of spinal cord. Biopsy from the cord lesion was suggestive of meningeal melanoma. Here we document a rare case of late onset NCM with intracranial meningeal infiltration and asymptomatic large epidural lesion of spinal cord, expanding its phenotypic spectrum. Optic neuropathy in NCM has not been reported earlier. Periodic screening of brain and spine is recommended for early prognostication and lesion identification in NCM.</p></div>","PeriodicalId":37974,"journal":{"name":"eNeurologicalSci","volume":"35 ","pages":"Article 100504"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S240565022400011X/pdfft?md5=b5f85e5f1c0ac067ac8a2e5fec8fa6c9&pid=1-s2.0-S240565022400011X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141048280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of lactulose on constipation in patients with Parkinson's disease: An exploratory pilot study","authors":"Shin-ichiro Kubo ,&nbsp;Mako Ito ,&nbsp;Kyoko Matsuba ,&nbsp;Tomohiro Shimono","doi":"10.1016/j.ensci.2024.100503","DOIUrl":"https://doi.org/10.1016/j.ensci.2024.100503","url":null,"abstract":"<div><h3>Introduction</h3><p>Constipation is one of the most common non-motor symptoms of Parkinson's disease (PD) and is associated with reduced quality of life in patients with PD. The aim of this study was to evaluate the effect of lactulose on defecation status in patients with PD.</p></div><div><h3>Methods</h3><p>In this open-label, single-center, exploratory pilot study, twenty-nine patients with PD received lactulose for three weeks for the treatment of constipation. The primary endpoint was the number of spontaneous bowel movements (SBMs). The secondary endpoints were stool consistency (Bristol Stool Form Scale [BSFS]) and the number of rescue laxatives used.</p></div><div><h3>Results</h3><p>Twenty-five patients with PD completed the study. The number of SBMs recorded during the lactulose intervention period was significantly increased compared with that recorded during the pre-intervention period. During the intervention period, the BSFS scores of the patients increased significantly, whereas the number of rescue laxatives they used decreased significantly. No serious adverse events were observed during the study period. Lactulose was well-tolerated.</p></div><div><h3>Conclusions</h3><p>The results of this study suggest that lactulose may be effective in improving defecation status in patients with PD. Further randomized controlled trials are needed to confirm the effects of lactulose on constipation in patients with PD.</p></div>","PeriodicalId":37974,"journal":{"name":"eNeurologicalSci","volume":"35 ","pages":"Article 100503"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2405650224000108/pdfft?md5=706b2ea7d0dadf2220a004c2d28e8cf8&pid=1-s2.0-S2405650224000108-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140914301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A decade with anomic primary progressive aphasia","authors":"Shoko Ota ,&nbsp;Kazuo Kakinuma ,&nbsp;Wataru Narita ,&nbsp;Yoshiyuki Nishio ,&nbsp;Nobuko Kawakami ,&nbsp;Ayane Tamagake ,&nbsp;Shigenori Kanno ,&nbsp;Minoru Matsuda ,&nbsp;Kyoko Suzuki","doi":"10.1016/j.ensci.2024.100508","DOIUrl":"https://doi.org/10.1016/j.ensci.2024.100508","url":null,"abstract":"<div><p>Some patients with primary progressive aphasia (PPA) demonstrate only anomia. The lack of longitudinal observations of anomic PPA precluded us from determining whether progressive anomic aphasia was simply an early stage of semantic or logopenic variants, or a relatively independent variant. Herein, we report the 10-year clinical course of a patient with PPA who presented with pure anomic aphasia for 9 years. He is a right-handed man with anomia, who noticed word-finding difficulty at age 73. He was admitted to the hospital at age 77. On admission, the patient showed pure anomic aphasia with preserved other language function. Episodic memory and visuospatial function were preserved. Magnetic resonance imaging (MRI) revealed left temporal lobe atrophy. At 82 years of age, the patient presented with pure anomic aphasia. At 83 years old, he showed mild impairment in word comprehension and semantic memory, in addition to anomia. MRI demonstrated further atrophy in the bilateral anterior temporal lobes, predominantly on the left side. This case suggests the possibility of slowly progressive, late-onset anomic PPA, which could be differentiated from the early stage of semantic or logopenic variants.</p></div>","PeriodicalId":37974,"journal":{"name":"eNeurologicalSci","volume":"35 ","pages":"Article 100508"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2405650224000157/pdfft?md5=5f14ff35ae069e1058244099cd7eff13&pid=1-s2.0-S2405650224000157-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141291124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"“Transcranial direct current stimulation for chronic foot pain: A comprehensive review”","authors":"Roberto Tedeschi","doi":"10.1016/j.ensci.2024.100498","DOIUrl":"https://doi.org/10.1016/j.ensci.2024.100498","url":null,"abstract":"<div><h3>Background</h3><p>Chronic foot pain, including conditions such as plantar fasciitis, presents a significant challenge to patients and healthcare providers. Traditional treatments often offer limited relief, prompting exploration of alternative therapies. Transcranial direct current stimulation (tDCS) has emerged as a noninvasive brain stimulation technique with potential for alleviating chronic pain syndromes.</p></div><div><h3>Methods</h3><p>A review was conducted following the JBI methodology and adhering to PRISMA guidelines. Searches were performed in databases including MEDLINE, Cochrane Central, Scopus, and PEDro, supplemented by grey literature sources and expert consultations. Studies were included if they investigated tDCS as an intervention for chronic foot pain, assessed its efficacy, safety, or mechanisms of action, and were published in English.</p></div><div><h3>Results</h3><p>A total of three papers were included in the review. The findings indicate that tDCS holds promise for managing chronic foot pain, including plantar fasciitis. Main results suggest significant reductions in pain intensity and improvements in related outcomes following tDCS treatment.</p></div><div><h3>Conclusions</h3><p>This review underscores the potential of tDCS as an alternative therapy for severe lower-extremity pain, highlighting the need for further research to optimize its parameters and long-term effects. tDCS emerges as a promising neuromodulation approach for chronic foot pain management, offering insights for enhancing patient outcomes and quality of life.</p></div>","PeriodicalId":37974,"journal":{"name":"eNeurologicalSci","volume":"35 ","pages":"Article 100498"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2405650224000054/pdfft?md5=0a26cdebe6f237a2349933d26c5ad9bc&pid=1-s2.0-S2405650224000054-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140191060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}